Patients with HIV-related facial lipoatrophy that receive Bio-Alcamid (polyalkylimide) filler experience a high risk of infection.
Studies that once supported the use of Bio-Alcamid are now considered erroneous and Polymekon–the company that manufactured it—went out of business.
Doctors have noticed that some patients develop infections years after the treatment.
Read more: